Hinge Health, Inc.
NYSE:HNGEMedical - Healthcare Information Services
-$0.24 today
- Market cap
- $9.31B
- Beta
- 1.99
- P/E (TTM)
- -10.3
- EPS (TTM)
- -$6.49
Volume 1.23M
Average 1.34M
HNGE EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Hinge Health, Inc.NYSE: HNGE
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) turns positive
Q2 FY2026 EPS (Diluted) was $0.53, compared with -$7.38 a year earlier. Trailing-twelve-month EPS (Diluted) was $1.29.
Context
- EPS (Diluted) grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 9 analysts of $2.52 (+148.5%) for the fiscal year ending Dec 2026, a step up from the -3360.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.53+29.3% QoQ
- Last fiscal yearDec 2025
- -$5.19-3360.0% YoY
- LTMJun 2026
- $1.29+123.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +107.2% | +2560.2% | +2453.0 pp |
| 1 year | -3360.0% | +148.5% | +3508.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (5.19) USD
- Year-over-year change
- -3360.0%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.19) | -3360.0% |
| FY2024 | 2024-12-31 | (0.15) | +89.2% |
| FY2023 | 2023-12-31 | (1.39) | — |
EPS (Diluted) vs competitors
How HNGE compares with its peers on the latest reported figures
- HNGE's LTM Jun 2026 EPS (Diluted) of $1.29 is the 2nd highest of the 5 companies compared; the peer median is $0.2.
- Its year-over-year change of +123.5% is the highest of 5, against a peer median of +4.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | $1.44 | +53.2% | +42.3% | |
| LTM Jun 2026 | $1.29 | +123.5% | — | |
| LTM Mar 2026 | $0.5 | -77.1% | -24.8% | |
| LTM Mar 2026 | -$0.11 | +83.9% | — | |
| LTM Apr 2026 | -$20.02 | -43.5% | — | |
| Peer median (excluding HNGE) | $0.2 | +4.8% | +8.7% | |
Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.4M | 587.86M |
| Cost of Revenue | 98.55M | 89.81M | 118.56M |
| Gross Profit | 194.18M | 300.59M | 469.3M |
| Gross Margin | 66.3% | 77.0% | 79.8% |
| Research & Development | 110.06M | 100.84M | 368.14M |
| Selling, General & Admin | 214.64M | 227.54M | 639.41M |
| Operating Expenses | 324.69M | 332.5M | 1.02B |
| Depreciation & Amortization | 5.63M | 5.95M | 5.13M |
| EBITDA | (124.89M) | (18.48M) | (535.89M) |
| EBITDA Margin | -42.7% | -4.7% | -91.2% |
| Operating Income | (130.51M) | (31.91M) | (546.37M) |
| Operating Margin | -44.6% | -8.2% | -92.9% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 21.97M | 20.65M | 19.11M |
| Income Before Tax | (108.55M) | (11.26M) | (527.26M) |
| Pre-Tax Margin | -37.1% | -2.9% | -89.7% |
| Income Tax Expense | (405K) | 677K | 998K |
| Net Income | (108.14M) | (11.93M) | (528.26M) |
| Net Margin | -36.9% | -3.1% | -89.9% |
| EPS (Basic) | (1.39) | (0.15) | (5.36) |
| EPS (Diluted) | (1.39) | (0.15) | (5.19) |
| Weighted Avg Shares | 78.02M | 78.02M | 79.19M |
| Weighted Avg Shares (Diluted) | 78.02M | 78.02M | 81.7M |
Hinge Health, Inc.
NYSE:HNGE
Intrinsic Alpha fair value
Locked
Current Price
$114.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.